276 related articles for article (PubMed ID: 23987798)
1. Marked and persistent eosinophilia in the absence of clinical manifestations.
Chen YY; Khoury P; Ware JM; Holland-Thomas NC; Stoddard JL; Gurprasad S; Waldner AJ; Klion AD
J Allergy Clin Immunol; 2014 Apr; 133(4):1195-202. PubMed ID: 23987798
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance.
Helbig G; Hus M; Francuz T; Dziaczkowska-Suszek J; Soja A; Kyrcz-Krzemień S
Med Oncol; 2014 Jan; 31(1):815. PubMed ID: 24338273
[TBL] [Abstract][Full Text] [Related]
3. Causes of hypereosinophilia in 100 consecutive patients.
Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC
Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
5. New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.
Berki T; Dávid M; Bóné B; Losonczy H; Vass J; Németh P
Pathol Oncol Res; 2001; 7(4):292-7. PubMed ID: 11882909
[TBL] [Abstract][Full Text] [Related]
6. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome.
Khoury P; Zagallo P; Talar-Williams C; Santos CS; Dinerman E; Holland NC; Klion AD
Allergy; 2012 Sep; 67(9):1149-56. PubMed ID: 22775568
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
8. Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
BMC Pulm Med; 2019 Aug; 19(1):158. PubMed ID: 31438916
[TBL] [Abstract][Full Text] [Related]
9. Siglec-7 on peripheral blood eosinophils: Surface expression and function.
Legrand F; Landolina N; Zaffran I; Emeh RO; Chen E; Klion AD; Levi-Schaffer F
Allergy; 2019 Jul; 74(7):1257-1265. PubMed ID: 30690753
[TBL] [Abstract][Full Text] [Related]
10. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome.
Prin L; Plumas J; Gruart V; Loiseau S; Aldebert D; Ameisen JC; Vermersch A; Fenaux P; Bletry O; Capron M
Blood; 1991 Nov; 78(10):2626-32. PubMed ID: 1726707
[TBL] [Abstract][Full Text] [Related]
12. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.
Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A
Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573
[TBL] [Abstract][Full Text] [Related]
14. Advances in diagnosis and treatment of eosinophilia.
Sheikh J; Weller PF
Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198
[TBL] [Abstract][Full Text] [Related]
15. IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis.
Wilson TM; Maric I; Shukla J; Brown M; Santos C; Simakova O; Khoury P; Fay MP; Kozhich A; Kolbeck R; Metcalfe DD; Klion AD
J Allergy Clin Immunol; 2011 Nov; 128(5):1086-92.e1-3. PubMed ID: 21762978
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
Stokes K; Yoon P; Makiya M; Gebreegziabher M; Holland-Thomas N; Ware J; Wetzler L; Khoury P; Klion AD
Clin Exp Allergy; 2019 Dec; 49(12):1598-1604. PubMed ID: 31657082
[TBL] [Abstract][Full Text] [Related]
17. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
18. Hypereosinophilia in Children and Adults: A Retrospective Comparison.
Williams KW; Ware J; Abiodun A; Holland-Thomas NC; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2016; 4(5):941-947.e1. PubMed ID: 27130711
[TBL] [Abstract][Full Text] [Related]
19. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
Khoury P; Abiodun AO; Holland-Thomas N; Fay MP; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(1):190-195. PubMed ID: 28757367
[TBL] [Abstract][Full Text] [Related]
20. [The Lymphoid Variant of HES (L-HES) as Differential Diagnose of Severe Asthma in Childhood].
Leu T; Rauthe S; Wirth C; Simon HU; Kunzmann V; Hebestreit H; Kunzmann S
Klin Padiatr; 2016 Nov; 228(6-07):319-324. PubMed ID: 27846662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
